Johnson & Johnson has agreed to buy surgical robotics company Auris Health Inc. for about $3.4 billion in cash, in a deal that would give the drug giant a diagnostic and treatment tool for lung cancer.
Under the terms of the deal announced Wednesday, J&J could also make additional payments of up to $2.35 billion to Auris based on milestones, people familiar with the deal said. Auris, a closely held firm led by industry veteran Fred Moll, has developed robotic surgical scopes operated with a hand-held device that are steered into patients’ lungs to identify cancerous tumors.
Auris will be part of J&J’s medical devices division. The world’s largest maker of healthcare products, J&J also has a robotic-surgery company called Verb Surgical Inc. that it formed with Verily Life Sciences, part of Google parent Alphabet Inc., in late 2015.
“What we’re trying to really garner is to convene this community of world-class robotics expertise,” Ashley McEvoy, chairwoman of J&J’s medical devices unit, said.
Moll will join J&J after the deal closes, which is expected by the end of the second quarter. He was the founder of Intuitive Surgical Inc., a pioneer in robotic laparoscopic surgery tools now valued at roughly $60 billion.
Deal-making is heating up in the medical technology industry as device makers hunt for innovative products to boost growth. In December, Medtronic completed a $1.7-billion deal to acquire Mazor Robotics Ltd., an Israeli company whose robotics-assisted products aid in spine and brain surgeries. Auris’ most recent funding round valued the Redwood City, Calif., company at about $2 billion.
Medical companies around the world are racing to develop technologies that make surgeries safer and less invasive. Auris and a subsidiary of J&J’s medical devices business entered a partnership in May to develop integrated systems for robotic control, navigation and application of microwave ablation via bronchoscopes.
Acquiring Auris will help J&J develop digital tools for diagnosis and early-stage intervention in lung cancer, an area where the company has been increasingly focused.
“The focus of our lung cancer team has really been around getting early access and visibility to the disease earlier on to get it diagnosed so you can provide appropriate treatment,” McEvoy said.